

Usha Panchapakesan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7667272/publications.pdf>

Version: 2024-02-01

23
papers

1,079
citations

471509

17
h-index

642732

23
g-index

23
all docs

23
docs citations

23
times ranked

1904
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?. PLoS ONE, 2013, 8, e54442.	2.5	224
2	Once daily administration of the SGLT2 inhibitor, empagliflozin, attenuates markers of renal fibrosis without improving albuminuria in diabetic db/db mice. Scientific Reports, 2016, 6, 26428.	3.3	119
3	TLR4 Activation Promotes Podocyte Injury and Interstitial Fibrosis in Diabetic Nephropathy. PLoS ONE, 2014, 9, e97985.	2.5	111
4	The Role of TLR2 and 4-Mediated Inflammatory Pathways in Endothelial Cells Exposed to High Glucose. PLoS ONE, 2014, 9, e108844.	2.5	91
5	Role of Toll-like receptors in diabetic nephropathy. Clinical Science, 2014, 126, 685-694.	4.3	63
6	Inhibition of Kidney Proximal Tubular Glucose Reabsorption Does Not Prevent against Diabetic Nephropathy in Type 1 Diabetic eNOS Knockout Mice. PLoS ONE, 2014, 9, e108994.	2.5	58
7	Saxagliptin reduces renal tubulointerstitial inflammation, hypertrophy and fibrosis in diabetes. Nephrology, 2016, 21, 423-431.	1.6	55
8	Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease. Clinical Science, 2013, 124, 17-26.	4.3	52
9	Drug repurposing in kidney disease. Kidney International, 2018, 94, 40-48.	5.2	41
10	Drug Insight: thiazolidinediones and diabetic nephropathy—relevance to renoprotection. Nature Clinical Practice Nephrology, 2005, 1, 33-43.	2.0	39
11	The Role of Dipeptidyl Peptidase – 4 Inhibitors in Diabetic Kidney Disease. Frontiers in Immunology, 2015, 6, 443.	4.8	35
12	Review article: Importance of the kidney proximal tubular cells in thiazolidinedione—mediated sodium and water uptake. Nephrology, 2009, 14, 298-301.	1.6	26
13	The role of toll-like receptors in diabetic kidney disease. Current Opinion in Nephrology and Hypertension, 2018, 27, 30-34.	2.0	25
14	Linagliptin Limits High Glucose Induced Conversion of Latent to Active TGFβ through Interaction with CIM6PR and Limits Renal Tubulointerstitial Fibronectin. PLoS ONE, 2015, 10, e0141143.	2.5	24
15	Renal epidermal growth factor receptor: Its role in sodium and water homeostasis in diabetic nephropathy. Clinical and Experimental Pharmacology and Physiology, 2011, 38, 84-88.	1.9	23
16	Requirement for TLR2 in the development of albuminuria, inflammation and fibrosis in experimental diabetic nephropathy. International Journal of Clinical and Experimental Pathology, 2014, 7, 481-95.	0.5	21
17	DPP-4 Inhibitors—Renoprotection in Diabetic Nephropathy?. Diabetes, 2014, 63, 1829-1830.	0.6	19
18	The Dipeptidyl Peptidase-4 Inhibitor Linagliptin Preserves Endothelial Function in Mesenteric Arteries from Type 1 Diabetic Rats without Decreasing Plasma Glucose. PLoS ONE, 2015, 10, e0143941.	2.5	17

#	ARTICLE	IF	CITATIONS
19	Long non-coding RNAs towards precision medicine in diabetic kidney disease?. <i>Clinical Science</i> , 2016, 130, 1599-1602.	4.3	15
20	Nanomedicines in the treatment of anemia in renal disease: focus on CERA (Continuous Erythropoietin) Tj ETQq0 0.0,rgBT /Overlock 10	6.7	12
21	The primary cilia in diabetic kidney disease: A tubulocentric view?. <i>International Journal of Biochemistry and Cell Biology</i> , 2020, 122, 105718.	2.8	4
22	Organ protection beyond glycaemic control with SGLT2 inhibitors. <i>Nature Reviews Nephrology</i> , 2021, 17, 223-224.	9.6	4
23	The authors reply. <i>Kidney International</i> , 2018, 94, 831.	5.2	1